Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis

被引:1
|
作者
Lubovich, Silvina [1 ]
Zaragoza, Silvina [1 ]
Rodriguez, Viviana [1 ]
Buendia, Jefferson [2 ]
Camargo Vargas, Bethy [1 ]
Alchundia Moreira, Jessica [1 ]
Galanternik, Laura [3 ]
Ratto, Patricia [4 ]
Teper, Alejandro [1 ]
机构
[1] Hosp Ninos Dr Ricardo Gutierrez, Unit 3, Resp Ctr, Buenos Aires, DF, Argentina
[2] Hosp Italiano Buenos Aires, Div Pediat Pulmonol, Buenos Aires, DF, Argentina
[3] Hosp Ninos Dr Ricardo Gutierrez, Dept Microbiol, Buenos Aires, DF, Argentina
[4] Hosp Ninos Dr Ricardo Gutierrez, Dept Kinesiol, Buenos Aires, DF, Argentina
来源
ARCHIVOS ARGENTINOS DE PEDIATRIA | 2019年 / 117卷 / 05期
关键词
pulmonary exacerbations; cystic fibrosis; PSEUDOMONAS-AERUGINOSA; OUTCOMES; CHILDREN; IMPACT; LIFE;
D O I
10.5546/aap.2019.eng.e466
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction. Cystic fibrosis patients develop pulmonary exacerbations (PEs) that require intravenous treatment. The objective of this study was to determine the risk factors associated with PEs and establish the percentage of patients who failed to recover their lung function. Population and methods. Observational, retrospective, cohort study. The medical records of cystic fibrosis patients seen at Hospital de Ninos Ricardo Gutierrez in 2013 were reviewed. Patients were divided into group 1, with PE (Fuchs criteria), and group 2, without PE. Age, sex, p.F508del mutation, percentage of baseline forced expiratory volume in the first second, baseline body mass index Z-score, chronic Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Burkholderia cepacia complex colonization (Leeds criteria), percentage of cystic fibrosis-related diabetes, and recovery of baseline forced expiratory volume in the first second were recorded. Results. A total of 117 patients were included. Group 1: 50, group 2: 67 patients. PEs were associated with a lower body mass index Z-score (RR: 1.45; p = 0.002), p.F508del mutation (RR: 3.23; p = 0.05), and chronic Burkholderia cepacia complex (RR: 3.69; p = 0.002), Pseudomonas aeruginosa (RR: 1.89; p = 0.01) and methicillin-resistant Staphylococcus aureus colonization (RR: 2.32; p = 0.002). Twenty-four percent of patients failed to recover their lung function. Conclusions. The presence of the p. F508del mutation, a poor nutritional status, and chronic colonization were the risk factors for exacerbation. A fourth of patients failed to recover their lung function.
引用
收藏
页码:E466 / E471
页数:6
相关论文
共 50 条
  • [31] Vitamin D Deficiency in Pediatric Patients with Cystic Fibrosis: Associated Risk Factors in the Northern United States
    Lansing, Amy Hughes
    McDonald, Catherine
    Patel, Raza A.
    Meihls, Suzanne
    Crowell, Kody
    Chatfield, Barbara
    Pohl, John F.
    SOUTHERN MEDICAL JOURNAL, 2015, 108 (03) : 164 - 169
  • [32] Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations
    Cogen, Jonathan D.
    Oron, Assaf P.
    Gibson, Ronald L.
    Hoffman, Lucas R.
    Kronman, Matthew P.
    Ong, Thida
    Rosenfeld, Margaret
    PEDIATRICS, 2017, 139 (02)
  • [33] The role of inflammation in cystic fibrosis pulmonary exacerbations
    Houston, Claire J.
    Taggart, Clifford C.
    Downey, Damian G.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (09) : 889 - 903
  • [34] Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis
    Waters, Valerie
    Stanojevic, Sanja
    Ratjen, Felix
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (11) : 1221 - 1228
  • [35] Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis
    Asner, Sandra
    Waters, Valerie
    Solomon, Melinda
    Yau, Yvonne
    Richardson, Susan E.
    Grasemann, Hartmut
    Gharabaghi, Farhad
    Tran, Dat
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (05) : 433 - 439
  • [36] Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations
    Cogen, Jonathan D.
    Faino, Anna, V
    Onchiri, Frankline
    Hoffman, Lucas R.
    Kronman, Matthew P.
    Nichols, David P.
    Rosenfeld, Margaret
    Gibson, Ronald L.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : 1589 - 1596
  • [37] Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population
    Albright, Jared C.
    Houck, Andrew P.
    Pettit, Rebecca S.
    PEDIATRIC PULMONOLOGY, 2020, 55 (10) : 2662 - 2666
  • [38] Vitamins a and e and pulmonary exacerbations in patients with cystic fibrosis
    Hakim, Fahed
    Kerem, Eitan
    Rivlin, Joseph
    Bentur, Lea
    Stankiewicz, Halina
    Bdolach-Abram, Tali
    Wischanski, Michael
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 45 (03) : 347 - 353
  • [39] Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice
    Luis Justicia, Jose
    Sole, Amparo
    Quintana-Gallego, Esther
    Gartner, Silvia
    de Gracia, Javier
    Prados, Concepcion
    Maiz, Luis
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (02) : 183 - 194
  • [40] Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis
    Waters, Valerie
    Stanojevic, Sanja
    Atenafu, Eshetu G.
    Lu, Annie
    Yau, Yvonne
    Tullis, Elizabeth
    Ratjen, Felix
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) : 61 - 66